Otostegia fruticosa
Otostegia fruticosa · Accepted scientific name
Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆
Otostegia fruticosa is a medicinal plant that has garnered significant scientific interest due to its potential anticancer activities. Recent studies have focused on its therapeutic application specifically against breast cancer cells. The plant contains valuable bioactive compounds, most notably the flavonoids hyperoside and rutin. Research often utilizes a methanolic extract to isolate these potent chemical constituents for testing. Understanding these properties provides crucial insights into the plant's role in modern pharmacological development.
- Synonyms
- Clinopodium Fruticosum
- Common names
- Not available
- Family
- Lamiaceae
- Distribution
- Not available
- Plant Parts
- Not available
Classification
Common Names
Otostegia fruticosa is a distinctive shrub that holds a special place in local botanical lore. Known by its common Hebrew name אודנה שיחנית, this plant is easily recognized by its unique structural characteristics. It thrives in specific environments where its hardy nature allows it to flourish alongside other Mediterranean species. Understanding its nomenclature helps enthusiasts connect more deeply with the diverse flora of the region. By studying this plant, one gains a better appreciation for the intricate naming traditions used to categorize the natural world.
Sources: Catalogue of Life (COL)
Synonyms
Otostegia fruticosa is a botanical subject that is frequently identified by its alternative scientific name, Clinopodium fruticosum. This synonymy can often cause confusion for researchers and enthusiasts navigating various taxonomic databases. Understanding that these two names refer to the exact same species is essential for accurate botanical documentation. As scientific classifications evolve, such nomenclature shifts reflect the ongoing efforts to refine our knowledge of the plant kingdom. Consequently, recognizing these linguistic links ensures that information regarding this specific shrub remains consistent across different studies.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Otostegia fruticosa is a distinctive species belonging to the vast kingdom Plantae. Within this biological realm, the plant is classified under the class Equisetopsida. It further falls into the order Lamiales, a group that characterizes many important flowering plants. As a member of the Lamiaceae family, it shares structural traits with other well-known aromatic herbs. Ultimately, this species is defined by its unique position within the genus Otostegia.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Lamiales |
| Family | Lamiaceae |
| Genus | Otostegia |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Otostegia fruticosa is a resilient plant species primarily found across the diverse landscapes of Africa. Its distribution spans much of Northeast Tropical Africa, including the nations of Djibouti, Eritrea, and Ethiopia. The plant also extends its reach into the regions of Sudan and South Sudan, demonstrating adaptability to varied environments. Furthermore, its presence is noted within Northern Africa, specifically throughout Egypt. This wide geographical range highlights the significant ecological footprint of the species across the continent.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Otostegia fruticosa is characterized by its distinct shrub-like growth form. This resilient plant is naturally self-supporting, allowing it to maintain its structure independently in its environment.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Otostegia fruticosa has emerged as a promising candidate in the ongoing search for new anticancer treatments. Recent studies have focused on its methanolic extract, specifically testing its cytotoxic effects against the human MCF-7 breast cancer cell line. Through both in-vitro and in-silico analysis, researchers identified key bioactive compounds like hyperoside and rutin that interact with the estrogen alpha receptor. While its potency is currently milder than the standard drug doxorubicin, the plant shows significant potential for therapeutic development. These findings suggest that this species could become a valuable addition to the medicinal arsenal used to combat breast cancer.
Compounds
Otostegia fruticosa is emerging as a significant medicinal plant in the ongoing search for new breast cancer treatments. Recent biochemical analyses have identified several key bioactive compounds within its methanolic extract. Specifically, the plant contains hyperoside, which has demonstrated potential through advanced molecular modeling. Additionally, the presence of rutin contributes to the plant's complex chemical profile. These findings suggest that the interaction of these compounds with estrogen receptors could make the species a valuable asset in oncology research.
Conditions
Otostegia fruticosa shows potential as a new defensive tool in the fight against breast cancer through its bioactive compounds. Research utilizing both in-vitro and in-silico methods demonstrates that its methanolic extract possesses cytotoxic activity against the MCF-7 human breast cancer cell line. Specific compounds within the plant, such as 3,5-di-O-dicaffeoylquinic acid, hyperoside, and rutin, were identified as key contributors to this effect. These substances exhibit binding and antagonistic interactions with the estrogen alpha receptor similar to the drug tamoxifen. Ultimately, these findings suggest that the plant can serve as a valuable addition to the pharmacological arsenal used to combat this disease.
Preparations
Otostegia fruticosa is prepared as a methanolic extract to evaluate its potential pharmacological properties. This specific preparation was tested for its in-vitro cytotoxic activity against the MCF-7 human breast cancer cell line. The study revealed that the methanolic extract possesses mildly potent anticancer activity. Researchers utilized HPLC-MS/MS techniques to identify the major compounds within this extract. Through molecular modeling, specific constituents of the extract were found to interact with the estrogen alpha receptor.